Sanofi Sees Booster Role For Covid Vaccine After Solid But Underwhelming Results

Lower Efficacy In Older Adults

 
• By Andrew McConaghie

Once expected to play a key role in beating COVID-19, Sanofi and GSK now see their vaccine as most likely to be used as a booster.

Sanofi_Berlin
A lower immune response in older adults was the problem which delayed the vaccine's development, but may not have been entirely resolved.

More from Business

More from Scrip